Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone

Translational Research

Volumn 156, Issue 2, 2010, Pages 55-67

  Evans, Patricia ^a   Kayyali, Reem ^b   Hider, Robert C ^c   Eccleston, John ^d   Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIC CITRATE FE 59;

ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON CHELATION; PRIORITY JOURNAL; REACTION TIME; SPECTROMETRY; THALASSEMIA MAJOR;

EID: 77955379581     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2010.05.002     Document Type: Article

References (40)

1. C. Hershko, G. Graham, G.W. Bates, and E.A. Rachmilewitz Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity Br J Haematol 40 1978 255 263
2. G.Y. Oudit, H. Sun, and M.G. Trivieri L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy Nat Med 9 2003 1187 1194
3. J.B. Porter, R. Rafique, and S. Srichairatanakool Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use Ann N Y Acad Sci 1054 2005 155 168
4. J.B. Porter, R.D. Abeysinghe, L. Marshall, R.C. Hider, and S. Singh Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 1996 705 713
5. W. Breuer, M.J. Ermers, P. Pootrakul, A. Abramov, C. Hershko, and Z.I. Cabantchik Desferrioxamine-chelatable iron, a component of serum non-transferrin- bound iron, used for assessing chelation therapy Blood 97 2001 792 798
6. R.W. Evans, R. Rafique, and A. Zarea Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera J Biol Inorg Chem 13 2008 57 74
7. A.M. Silva, X. Kong, M.C. Parkin, R. Cammack, and R.C. Hider Iron(III) citrate speciation in aqueous solution Dalton Trans 2009 8616 8625
8. A.M. Silva, and R.C. Hider Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation Biochim Biophys Acta 1794 2009 1449 1458
9. F.N. al-Refaie, D.G. Wickens, B. Wonke, G.J. Kontoghiorghes, and A.V. Hoffbrand Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1 Br J Haematol 82 1992 431 436
10. P. Pootrakul, P. Sirankapracha, and J. Sankote Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand Br J Haematol 122 2003 305 310
11. Z.I. Cabantchik, W. Breuer, G. Zanninelli, and P. Cianciulli LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol 18 2005 277 287
12. G. Zanninelli, W. Breuer, and Z.I. Cabantchik Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients Br J Haematol 147 2009 744 751
13. P.B. Walter, E.A. Macklin, and J. Porter Inflammation and oxidant-stress in {beta}-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial Haematologica 93 2008 817 825
14. P. May, and D. Williams Synergistic chelation therapy or mixed ligand complexes for plutonium or cadmium poisoning Nature 278 1979 581
15. S. Pollack, P. Aisen, F.D. Lasky, and G. Vanderhoff Chelate mediated transfer of iron from transferrin to desferrioxamine Br J Haematol 34 1976 231 235
16. G.E. Jackson, P.M. May, and D.R. Williams The action of chelating agents in the removal of copper from ceruloplasmin: an in vitro study FEBS Lett 90 1978 173 177
17. J. Schubert, and S.K. Derr Mixed ligand chelate therapy for plutonium and cadmium poisoning Nature 275 1978 311 313
18. Y. Aydinok, Z. Ulger, and D. Nart A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major Haematologica 92 2007 1599 1606
19. M.A. Tanner, R. Galanello, and C. Dessi A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance Circulation 115 2007 1876 1884
20. P.J. Giardina, and R.W. Grady Chelation therapy in beta-thalassemia: an optimistic update Semin Hematol 38 2001 360 366
21. R.W. Grady, and P.J. Giardina Iron chelation with oral deferiprone in patients with thalassemia N Engl J Med 339 1998 1712 1713 author reply 3-4
22. A. Martell The design and synthesis of chelating agents 1981 Elsevier North Holland Inc Amsterdam, The Netherlands
23. P. Ihnat, J. Vennerstrom, and D. Robinson Solution equilibria of deferoxamine amides J Pharm Sci 91 2002 1733 1741
24. R. Motekaitis, and A. Martell Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands Inorganica Chim Acta 183 1991 71 80
25. G. Link, A.M. Konijn, W. Breuer, Z.I. Cabantchik, and C. Hershko Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture J Lab Clin Med 138 2001 130 138
26. Srichairatanakool S, Kemp P, Porter JB. Evidence for "shuttle" effect of NTBI onto desferrioxamine in thalassaemic plasma in the presence of NTA. In: International Symposium: Iron in Biology and Medicine; 1997, St. Malo, France. p. 210.
27. B.P. Esposito, W. Breuer, P. Sirankapracha, P. Pootrakul, C. Hershko, and Z.I. Cabantchik Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 102 2003 2670 2677
28. P.S. Dobbin, R.C. Hider, and A.D. Hall Synthesis, physicochemical properties, and biological evaluation of N- substituted 2-alkyl-3-hydroxy-4(1H)- pyridinones: orally active iron chelators with clinical potential J Med Chem 36 1993 2448 2458
29. L. Alderighi, P. Gans, A. Ienco, D. Peters, A. Sabatini, and A. Vacca Hyperquad simulation and speciation (hyss): a utility program for the investigation of equilibria involving soluble and partially soluble species Coord Chem Rev 184 1999 311 318
30. S. Singh, R.C. Hider, and J.B. Porter A direct method for quantification of non-transferrin-bound iron Anal Biochem 186 1990 320 323
31. I. Gosriwatana, O. Loreal, S. Lu, P. Brissot, J. Porter, and R.C. Hider Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin Anal Biochem 273 1999 212 220
32. M. Grootveld, J.D. Bell, B. Halliwell, O.I. Aruoma, A. Bomford, and P.J. Sadler Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy J Biol Chem 264 1989 4417 4422
33. J.B. Porter Deferoxamine pharmacokinetics Semin Hematol 38 2001 63 68
34. F.N. al-Refaie, L.N. Sheppard, P. Nortey, B. Wonke, and A.V. Hoffbrand Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload Br J Haematol 89 1995 403 408
35. G.J. Kontoghiorghes, J.G. Goddard, A.N. Bartlett, and L. Sheppard Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one Clin Pharmacol 48 1990 255 261
36. J.P. Kushner, J.P. Porter, and N.F. Olivieri Secondary iron overload Hematology Am Soc Hematol Educ Program 2001 47 61
37. B. Faller, and H. Nick Kinetics and mechanism of iron(III) removal from citrate by desferrioxamine B and 3-hydroxy-1,2-dimethyl-4-pyridone J Am Chem Soc 116 1994 3860 3865
38. C.E. Lentner 1981 Ciba-Geigy Limited Geigy Scientific Tables Basle, Switzerland
39. C.E. Cooper, G.R. Lynagh, K.P. Hoyes, R.C. Hider, R. Cammack, and J.B. Porter The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase J Biol Chem 271 1996 20291 20299
40. R. Hider Nature of non-transferrin-bound iron Eur J Clin Invest 32 2002 S50 S54